Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers.

Trial Profile

Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker; Diagnostic use; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Mar 2013 Results have been presented at the 2013 AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy according to an Endocyte media release. Results were also summarised in the media release.
    • 13 Apr 2012 Actual patient number is 49 according to ClinicalTrials.gov.
    • 13 Apr 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top